EVAHEART 2 Left Ventricular Assist System: A Hemocompatible Centrifugal Pump with Physiological Pulsatility

Despite current advances in technology, continuous-flow left ventricular assist devices still exhibit clinical adverse events that limit patient quality of life. These hemocompatibility-related adverse events (HRAEs) include stroke, gastrointestinal bleeding, hemolysis, and pump thrombosis. The EVAHEART 2 centrifugal left ventricular assist system is designed to address the risks associated with HRAEs, thus contributing to long-term survival and a reduction in medical care costs. The EVAHEART 2 has also adopted a new tipless inflow cannula that minimizes the risk of ischemic stroke associated with cannula malposition in the left ventricle. The EVAHEART 2 is clinically available in Japan and is under investigation in a US clinical trial.